US Pharm. 2016;41(9):12.

Lakewood, CO—The synthetic peptide abaloparatide was found to significantly reduce the risk of new fractures in postmenopausal women with osteoporosis after 18 months of daily injection. In a multicountry randomized trial led by the Colorado Center for Bone Research, 1,901 postmenopausal women (mean age 69 years) with osteoporosis received active treatment (abaloparatide or teriparatide) or placebo for 18 months. New vertebral fractures occurred less often in the abaloparatide group (event rate: 2.7% for abaloparatide, 3.3% for teriparatide, and 4.7% for placebo). Increases in bone mineral density were greater with abaloparatide versus placebo, and the incidence of hypercalcemia was lower with abaloparatide versus teriparatide. There were no differences in serious adverse events between abaloparatide and teriparatide.

To comment on this article, contact